Endometrial cancer (EC) is the most common gynecologic malignancy, with worldwide increasing incidence and disease-associated mortality. Although most patients with EC are diagnosed with early-stage disease, systemic treatment options for patients with advanced or recurrent EC have historically been limited. EC-focused clinical trials and the ensuing therapeutic landscape have expanded since The Cancer Genome Atlas (TCGA) identified 4 distinct EC subgroups associated with differential survival. This endeavor revolutionized our understanding of the genomic characterization of EC as well as molecular drivers of this heterogeneous malignancy, leading to precision oncology approaches to therapeutics and advancement in treatment options. This review describes the current status of and recent advancements in therapeutic options for patients with advanced and recurrent EC. The NCCN Guidelines for Uterine Neoplasms provide detailed recommendations regarding the diagnosis, workup, and management of EC.
Submitted September 9, 2022; final revision received December 7, 2022; accepted for publication December 16, 2022.
Disclosures: Dr. Green has disclosed receiving institutional research support/grants from Mereo Biopharma and Eli Lilly. Dr. Makker has disclosed receiving research support/grants from Clovis, Merck, Eisai, Karyopharm, Faeth, Duality, and AstraZeneca; serving as a principal investigator for Clovis, Merck, Eisai, Karyopharm, Faeth, Duality, and AstraZeneca; and serving as an advisory board member for Eisai, Merck, Novartis, AstraZeneca, Clovis, Karyopharm, Faeth, Duality, and Morphosys. The remaining authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Funding: Dr. Green and Dr. Makker are supported in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.